TBPH
Theravance Biopharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$836.19M
P/E Ratio
7.27
EPS
$2.23
Beta
0.19
52W High
$21.03
52W Low
$9.10
50-Day MA
$15.82
200-Day MA
$16.22
Dividend Yield
—
Profit Margin
104.30%
Forward P/E
7.95
PEG Ratio
-0.05
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.
Fundamentals
| Revenue (TTM) | $109.78M |
| Gross Profit (TTM) | $77.98M |
| EBITDA | $6.58M |
| Operating Margin | -33.10% |
| Return on Equity | 50.20% |
| Return on Assets | 0.76% |
| Revenue/Share (TTM) | $2.17 |
| Book Value | $5.81 |
| Price-to-Book | 3.02 |
| Price-to-Sales (TTM) | 7.62 |
| EV/Revenue | 4.762 |
| EV/EBITDA | 3.70 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 15.00% |
| Shares Outstanding | $51.55M |
| Float | $24.04M |
| % Insiders | 4.74% |
| % Institutions | 98.89% |
Historical Volatility
HV 10-Day
20.79%
HV 20-Day
18.55%
HV 30-Day
21.63%
HV 60-Day
68.97%
HV Rank
0.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($17.20 target)
3
Buy3
HoldMore HEALTHCARE Stocks
Data last updated: 5/19/2026